PMID- 23737409 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20130606 LR - 20211021 IS - 1723-8617 (Print) IS - 2051-5545 (Electronic) IS - 1723-8617 (Linking) VI - 12 IP - 2 DP - 2013 Jun TI - Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia. PG - 99-107 LID - 10.1002/wps.20026 [doi] AB - Drug discovery based on classic models for cognitive impairment and negative symptoms of schizophrenia have met with only modest success. Because cognitive impairment and negative symptoms may result from disruptions in neurodevelopment, more complex developmental models that integrate environmental and genetic risk factors are needed. In addition, it has become clear that biochemical pathways involved in schizophrenia form complex, interconnected networks. Points at which risk factors converge, such as brain-derived neurotrophic factor (BDNF) and protein kinase B (AKT), and from which processes involved in neuroplasticity diverge, are of particular interest for pharmacologic interventions. This paper reviews elements of neurodevelopmental models for cognitive deficits and negative symptoms of schizophrenia with the aim of identifying potential targets for interventions. CI - Copyright (c) 2013 World Psychiatric Association. FAU - Goff, Donald C AU - Goff DC AD - Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, 140 Old Orangeburg Road, Orangeburg, NY, 10962, USA. LA - eng PT - Journal Article PL - Italy TA - World Psychiatry JT - World psychiatry : official journal of the World Psychiatric Association (WPA) JID - 101189643 PMC - PMC3683252 EDAT- 2013/06/06 06:00 MHDA- 2013/06/06 06:01 PMCR- 2013/06/01 CRDT- 2013/06/06 06:00 PHST- 2013/06/06 06:00 [entrez] PHST- 2013/06/06 06:00 [pubmed] PHST- 2013/06/06 06:01 [medline] PHST- 2013/06/01 00:00 [pmc-release] AID - 10.1002/wps.20026 [doi] PST - ppublish SO - World Psychiatry. 2013 Jun;12(2):99-107. doi: 10.1002/wps.20026.